ArticleFrontiers in public health2025
MDL-CA: a multimodal deep learning approach with a cross attention mechanism for accurate brain cancer diagnosis.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Leveraging pretrained vision transformers for classifying alcohol use disorder using raw resting-state EEG.Neuroimage. Reports · 2026Article
- Machine Learning for Radiomics in Oncology: Challenges, Limitations, and Future Directions.Sensors (Basel, Switzerland) · 2026Article
- miR-152-3p Overcomes Temozolomide Resistance in Glioblastoma by Targeting TGF-α and Enhancing Apoptosis.Oncology research · 2026Article
- Interpretability and performance of a 3D C-vit model for accurate grading of pediatric brain tumors.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brain cancer diagnosis poses a significant clinical challenge due to the complex interplay between molecular mechanisms and anatomical abnormalities. Traditional diagnostic techniques, including invasive biopsies, isolated genomic assays, and standalone Magnetic Resonance Imaging (MRI), often exhibit limitations such as procedural risks, inadequate sensitivity, and incomplete assessment of tumor heterogeneity. These shortcomings contribute to delayed diagnosis, inaccurate tumor grading, and suboptimal treatment planning. Furthermore, single-modality data, whether MRI or genomic profiles, frequently yield limited diagnostic accuracy and biological interpretability. Methods: To address these limitations, this study proposes MDL-CA, a Multimodal Deep Learning framework with a Cross-Attention mechanism, designed to integrate genomic and MRI modalities for enhanced brain cancer diagnosis. The framework fuses genomic graph embeddings, extracted using a Graph Attention Network (GAT), with MRI feature maps derived from a 3D DenseNet. The cross-modal attention fusion mechanism enables the model to capture intricate biological and spatial interactions, producing a biologically informed feature representation. Additionally, the Entmax sigmoid function is employed in the classification stage to promote sparsity and improve interpretability. Data were sourced from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA) following comprehensive preprocessing. Results: Extensive experiments conducted across four benchmark datasets demonstrated that MDL-CA achieved superior diagnostic performance, with accuracies of 96.22%, 97.14%, 98.46%, and 98.21%, and F1-scores ranging from 95.95% to 98.40%. These results confirm the framework's robustness, scalability, and consistent generalization across diverse datasets. Discussion: The integration of genomic and MRI data through the proposed cross-attention mechanism enables deeper biological understanding and improved diagnostic precision compared to single-modality and conventional fusion approaches. By effectively modeling interactions between molecular and anatomical features, MDL-CA advances the development of biologically informed, multimodal diagnostic systems for brain cancer. The results highlight the framework's potential to support early diagnosis and personalized treatment planning in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.